Are clinical trials safe?

Yes. Every study on QualifiedStudies is reviewed and approved by an Institutional Review Board (IRB) and conducted under FDA regulations. Research sites are HIPAA-covered entities, and you can withdraw at any time for any reason.

Do I get paid to participate in a clinical trial?

Most studies offer compensation for your time and travel. The amount varies by study length and visit schedule, and is disclosed up front before you enroll.

Is my health information kept private?

Yes. Your information is encrypted, never sold, and only shared with the specific research site you choose to apply to. Our handling of your data is governed by our Consumer Health Data Privacy Policy; the research sites you're matched with are HIPAA-covered entities.

How do I qualify for a clinical trial?

Take our free 60-second eligibility quiz. Enter your ZIP code, condition, and a few health details, and we'll match you with research sites near you that are actively enrolling participants.

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT ID: NCT07276581
Registry status: Recruiting
Study type: Interventional
Phase: Phase 2
Sponsor: AstraZeneca
Conditions: Rheumatoid Arthritis

Overview

ClinicalTrials.gov lists this study as Recruiting.

Official title: A Multicentre, Parallel-group, Phase II, Randomised, Double-blind, 4 Arm Study to Evaluate Efficacy and Safety of AZD1163 in Participants With Moderately-to-Severely Active Rheumatoid Arthritis (LaunchPAD-RA)

Enrollment: 320 participants (Estimated).

What is being studied

Drug: AZD1163
Other: Placebo

Who may be eligible

Ages: 18 Years to no maximum
Sex: All
Healthy volunteers accepted: No

ClinicalTrials.gov lists the following eligibility criteria.

* Inclusion * Diagnosed with adult-onset RA as defined by the 2010 ACR/EULAR classification criteria for at least 12 weeks prior to screening. * Moderately-to-severely active RA as defined by: a. \>= 6 swollen joints on 66SJC and \>= 6 tender joints on 68TJC; b. CRP \> upper limit of normal. * Have a positive ACPA at screening. * A history of inadequate response, or loss of response, or intolerance to: a. at least one csDMARD treatment, AND/OR b. At least one and at most 2 TNFi. * A history of at least 12 weeks treatment and \>= 4 weeks stable on a csDMARD and/or SC TNFi prior to the day of randomisation. * Exclusion * History or evidence of an alternate autoimmune or other condition that could confound the diagnosis of RA. Participants with RA and secondary Sjogren's disease are eligible. * Have received or planning to receive any biologic DMARDs (except for TNFi) or targeted synthetic DMARDs.

Study locations

122 study locations are listed.

Recruiting site status is explicitly provided for 122 locations; 38 are listed as Recruiting.

Countries: Argentina, Brazil, Bulgaria, Canada, Chile, China, Germany, Hungary, Japan, Mexico, Poland, Puerto Rico, South Africa, Spain, Ukraine, United Kingdom, United States

Ontario, Canada: 1
Quebec, Canada: 1
Arizona, United States: 3
California, United States: 3
Colorado, United States: 1
Florida, United States: 5
Georgia, United States: 1
Illinois, United States: 2
Louisiana, United States: 1
Maryland, United States: 1
Massachusetts, United States: 1
Missouri, United States: 2
Nevada, United States: 1
South Carolina, United States: 1
Texas, United States: 5

Sample of listed locations

Research Site — Caba, C1128AAF, Argentina — Recruiting
Research Site — Ciudad de Buenos Aires, C1015ABO, Argentina — Recruiting
Research Site — Córdoba, X5000EDC, Argentina — Recruiting
Research Site — San Isidro, 1643, Argentina — Recruiting
Research Site — San Miguel de Tucumán, T4000AXL, Argentina — Recruiting
Research Site — Windsor, Ontario, N8X 5A7, Canada — Recruiting
Research Site — Trois-Rivières, Quebec, G9A 3Y2, Canada — Recruiting
Research Site — Linyi, CN-276003, China — Recruiting
Research Site — Nanchong, 637000, China — Recruiting
Research Site — Panjin, 124000, China — Recruiting
Research Site — Pingxiang, 337055, China — Recruiting
Research Site — Fukuoka, 815-8555, Japan — Recruiting
Research Site — Hamamatsu, 430-0906, Japan — Recruiting
Research Site — Hitachi-Naka, 312-0057, Japan — Recruiting
Research Site — Iizuka-shi, 820-8505, Japan — Recruiting
Research Site — Kawachinagano-shi, 586-8521, Japan — Recruiting
Research Site — Meguro-ku, 152-8902, Japan — Recruiting
Research Site — Miyazaki, 880-0834, Japan — Recruiting
Research Site — Nagoya, 457-8511, Japan — Recruiting
Research Site — Sagamihara-shi, 252-0315, Japan — Recruiting
Research Site — Sasebo-shi, 857-1195, Japan — Recruiting
Research Site — Sayama-shi, 350-1305, Japan — Recruiting
Research Site — Ivano-Frankivsk, 76018, Ukraine — Recruiting
Research Site — Kyiv, 02002, Ukraine — Recruiting
Research Site — Uzhhorod, 88000, Ukraine — Recruiting

Study details

Start date: December 15, 2025
Primary completion date: November 12, 2027
Completion date: August 18, 2028
First posted: December 11, 2025

Source and update information

Source: ClinicalTrials.gov
NCT ID: NCT07276581
Registry last updated: June 24, 2026
QualifiedStudies registry data refreshed: October 2, 2026
QualifiedStudies record fetched: October 2, 2026

View NCT07276581 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Clinical trial FAQ